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S U M M A R Y
Objectives: Our objective was to identify evidence on the protection achieved by single-dose use of
inactivated hepatitis A vaccines in order to evaluate the potential of a ﬂexible booster administration in
the form of a second dose.
Methods: A search was conducted for evidence on single-dose administration of inactivated hepatitis A
vaccine and its potential impacts on long-term seropositivity rates. The main pharmaceutical vaccine
manufacturer federations and the corresponding authors of manuscripts were approached for additional
epidemiologic data. Correspondence was also sent to the Argentinean Ministry of Health.
Results: We identiﬁed 15 data sources reporting on protection achieved by a single dose of inactivated
hepatitis A vaccine. The consistent ﬁnding was that the immune and memory response to the booster
dose, or post-booster geometric mean titer, was independent of the time since initial vaccination. The
impact of the booster on seroprotection was the same across sexes and age-groups. The longest time
interval between initial and booster dose was 10.67 years, indicating that booster doses can be highly
immunogenic for up to 10.67 years after primary vaccination.
Conclusions: Protective anti-hepatitis A virus antibody levels after a single dose of inactivated hepatitis A
vaccine can persist for almost 11 years and increase or reappear after booster vaccination. Further
research on the vaccine doses needed to achieve long-term protection against hepatitis A infection is
required.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The hepatitis A virus (HAV) is a fecal–oral transmitted virus
with an annual infection incidence that is strongly inversely
related to levels of economic development and modern water
sanitation. The annual incidence of hepatitis A decreased between
1990 and 2005 as global economic development increased.1
Paradoxically, because the probability of symptomatic disease
resulting from incident infections increases as the age of infection
increases, the global burden of hepatitis A disease may have
increased over the time period during which incidence declined.
HAV infection and disease is preventable by early immunization
with inactivated and live-attenuated hepatitis A vaccines. (Live
attenuated hepatitis A vaccines are manufactured in China and are
used as a single dose, only in children, in some national
immunization programs.) Currently, inactivated HAV vaccines* Corresponding author.
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http://dx.doi.org/10.1016/j.ijid.2013.04.012are licensed for administration in a two-dose schedule given at 6–
12-month intervals (single dose plus booster dose in the form of a
second dose). However, previously published immunogenicity
studies and data indicate that inactivated hepatitis A vaccines such
as VAQTA (Merck),2 AVAXIM (Sanoﬁ Pasteur), HAVRIX,3–5 and
EPAXAL (Crucell)6 are highly protective after a single dose.
Barriers to the introduction of universal hepatitis A immuniza-
tion of children include high vaccine prices, complex vaccine
schedules, and cold chain requirements. The potential off-label use
of hepatitis A vaccines by means of single-dose administration are
also not well-deﬁned, but might be of relevance for public health
decision-making. The traditional Expanded Program on Immuni-
zation (EPI) schedule has not targeted children over the age of 1
year, although hepatitis A vaccines are registered for use after 1
year of age. The use of a single-dose schedule would remove
barriers to the use of these vaccines for public health purposes, by
allowing fewer contacts with children and thereby reducing the
costs associated with immunization.
During a meeting of the World Health Organization (WHO)
Strategic Advisory Group of Experts (SAGE) on Immunization inses. Published by Elsevier Ltd. All rights reserved.
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noted, especially the strong evidence for the efﬁcacy and safety of
both one- and two-dose inactivated hepatitis A vaccines.7 A
request was made for further evidence and review of the long-term
protection afforded by single-dose use of inactivated hepatitis A
vaccine. Therefore, we aimed to identify existing evidence for
protection achieved by single-dose use of inactivated hepatitis A
vaccines in order to amend hepatitis A vaccine recommendations.
We believe that data evaluating the potential of a ﬂexible dose
administration of this vaccine will be helpful for the global public
health control of hepatitis A, thereby helping to reduce the
tremendous burden associated with this disease.
2. Methods
We reviewed the published literature on the long-term
protection of hepatitis A vaccines in general by applying
systematic search approaches.8 Using references identiﬁed for
this previous review, we searched for evidence of single-dose
administration of inactivated hepatitis A vaccines and its potential
impact on long-term seropositivity rates pre-booster administra-
tion. We supplemented this review with a search for previously
unidentiﬁed gray literature and difﬁcult-to-access data by
approaching the main pharmaceutical vaccine manufacturer
federations (International Federation of Pharmaceutical Manufac-
turers and Associations (IFPMA) and Developing Countries Vaccine
Manufacturers Network (DCVMN)) and requested additional, more
recent epidemiologic data and information providing evidence on
single-dose administration and long-term immune protection
achieved by inactivated hepatitis A vaccines. Additional requests
for evidence were also sent to corresponding authors of manu-
scripts, as well as to the Argentinean Ministry of Health, since
Argentina was the ﬁrst country to implement a universal single-
dose hepatitis A immunization program starting in 2005.9
3. Results
We identiﬁed 15 data sources reporting on protection achieved
by a single dose of inactivated hepatitis A vaccine. Data were
collected in the following countries: Switzerland (n = 3), Nicaragua
(n = 2), Sweden (n = 2), USA (n = 2), Thailand (n = 1), Israel (n = 1),
Netherlands/France (n = 1), Russia (n = 1), and Argentina (n = 2).
Apart from one study in Russian,10 all studies were published in
English.
Uniformly, the objective of the studies measuring seroprotec-
tion rates (SPR) and/or geometric mean titers (GMT) was the
assessment of the response to a booster dose by time following the
ﬁrst dose. Table 1 shows the 13 studies and assessments that have
reported SPR and/or GMT achieved by single-dose administration
of inactivated hepatitis A vaccine with follow-up times >12
months after the initial immunization.4–6,14–19,21–24 Studies that
reported shorter intervals of follow-up were not considered to be
relevant, due to current vaccine recommendations and since they
do not provide information on longer term protection achieved by
single-dose administration (e.g., Bovier et al., 200511 or Shouval
et al., 1993,12 5 months). Out of all studies, nine were conducted
among adults, mostly among healthy travelers. Six of the
publications reported on children, including two studies that
evaluated the population impact (HAV incidence and fulminant
hepatic failure) of single-dose administration by means of
comparing pre- and post-vaccination period surveillance data.
Both of these studies were conducted in Argentina (Table 2).9,13
All studies reported observational outcome data (SPR, GMT) on
individuals who were HAV-naive at the time of enrolment in
randomized immunogenicity or effectiveness trials. It was
consistently found that the immune response to a booster dose,or post-booster GMT, was independent of the time since initial
vaccination. In addition, the impact of the booster on seropro-
tection was the same across sexes and age-groups. For EPAXAL,
no signiﬁcant difference in post-booster GMT was found
between those who received the booster dose at 18–29 months,
30–41 months, or 42–54 months after primary immunization.14
Hatz et al.15 also found that a delay in EPAXAL booster of up to
128 months did not inﬂuence the memory response to the
booster. For VAQTA, immune responses, SPR, and post-booster
GMTs were similar independent of the administration of a
booster dose at 12 or 18 months after the initial dose, or 6
months after primary immunization.16 For HAVRIX, delaying the
booster for 4–6 years did not inﬂuence the immunogenicity of
the boost, and all vaccines showed a high anamnestic booster
response.4 Another HAVRIX study conﬁrmed that there was no
signiﬁcant difference between pre-booster GMTs of a delayed
booster group (2 years follow-up, with a maximum of 66
months) and the group that followed the recommended
schedule.17 Similar results were observed for AVAXIM, indicat-
ing that the post-booster response was similar across the
different schedule groups.18
The longest time interval between initial and booster dose was
10.67 years and this indicates that a booster dose of inactivated
hepatitis A vaccine can be highly immunogenic for up to 10.67
years after primary vaccination. In addition, pre-booster SPRs were
similar across groups assigned to different time intervals of booster
administration.15
4. Discussion
We conducted a non-systematic review of the single-dose use
of inactivated hepatitis A vaccine. The evidence found on the
longest time interval suggests that protective anti-HAV antibody
levels after a single dose of inactivated hepatitis A vaccine can
persist for almost 11 years and increase or reappear after booster
vaccination. In line with the conclusions drawn by all of the studies
identiﬁed, it appears that there is no need for a booster dose of
hepatitis A vaccine within a time-frame of at least 6 years. Other
factors, such as anti-HAV endemicity levels, population-speciﬁc
factors, and the amount of antigen given in the primary vaccine
dose, might be further assessed.3
The studies considered have certain limitations. In some
instances where the study population was divided into subgroups
according to different observation times after single-dose vaccine
administration, it was not speciﬁed which individual had the
longest follow-up within the group of delayed booster recipients.
For example, Landry et al.17 stated that the follow-up time was 24
months with a maximum of 66 months between the primary and
booster dose administration, but did not indicate if there were
differences, e.g., socio-economic, between individuals in the
different groups according to length of delay.
Only measurable outcomes such as SPR were considered in the
studies, however immunological memory was not assessed
directly, as it was assumed to be the explanation for booster
responses. Several studies have shown that a booster response
does not require the existence of detectable anti-HAV antibodies
before the booster dose, since initial vaccination introduced
immunological memory (e.g., Iwarson et al.4). Although the
detection of residual antibody levels by assays is one of the main
correlates for immunity against hepatitis A, the detection of
antibodies is not the absolute requirement for protective
immunity and, depending on the research question, outcome
measures such as GMTs may not be appropriate.25 Nevertheless,
lower pre-booster antibody concentrations correlated signiﬁcantly
with lower post-booster values in one study,15 and most of the
studies assessed delays of booster doses of only up to a few years.19
Table 1
Seroprotection rates (SPRs) and geometric mean titers (GMTs) following single-dose administration of inactivated hepatitis A vaccines, by length of follow-up
Author Study type Intervention Population Outcome single dose vaccination Other results and comments
Beck et al., 200314 Open-label, non-comparative
study
EPAXAL, 0.5 ml 115 healthy adults aged 20–70
years, Switzerland
SPR (anti-HAV AB 20 mIU/ml):
18–29 months, 67%; 30–41
months, 77%; 42–54 months, 70%
SPR (anti-HAV AB 10 mIU/ml):
18–29 months, 89%; 30–41
months, 91%; 42–54 months, 85%
No signiﬁcant difference found for
GMT in dependence of booster
administration interval
Hatz et al., 201115 Observational data EPAXAL, 0.5ml 130 adults aged 20.5–73 years,
Switzerland
1999 study: 9–54 months
booster interval, 104 adults
2006 study: 98–128 months
booster interval, 26 adults
SPR all (anti-HAVAB20mIU/ml),
9–128 months: 46.2%
SPR all (anti-HAVAB10mIU/ml),
9–128 months: 59.2%
GMT all, 9–128months: 17 (95% CI
13–22)
SPR subgroup (n = 26) (anti-HAV
AB 20 mIU/ml), 98–128 months:
50%
SPR subgroup (n = 26) (anti-HAV
AB 10 mIU/ml), 98–128 months:
53.8%
GMT subgroup, 98–128 months:
24 (95% CI 14–41)
Sex-speciﬁc analysis:
SPR males (anti-HAV AB 20 mIU/
ml), 9–128 months: 27.6%
SPR males (anti-HAV AB 10 mIU/
ml), 9–128 months: 41.4%
SPR females (anti-HAV AB 20
mIU/ml), 9–128 months: 61.1%
SPR females (anti-HAV AB 10
mIU/ml), 9–128 months: 73.6%
Herzog 201021 Observational
seroepidemiology study
EPAXAL, 0.5 ml 130 children aged 2–17 years,
initially enrolled 2005,
Nicaragua
SPR of 101 vaccinated children
(anti-HAV AB 10 mIU/ml), 5.5
years: 95.1% (5 individuals
dropped below threshold)
GMC, 5.5 years: 74.4 (95%
CI 60–92)
Loss to follow-up until 2010: two
infected children and four of the
105 protected children
Hornick et al., 200116 Observational data based on
randomized vaccine trial
VAQTA, 50 U 360 adults aged 18–71 years,
randomized to three groups by
booster dose timing, USA
SPR group 3 (n = 118) (anti-HAV
AB 10 mIU/ml), 1.5 years: 96.6%
(95% CI 90.4–99.3%) (85/88)
GMT group 3, 1.5 years: 121.3 (95%
CI 90.9–161.8)
Comparable responses regardless
of booster dose administration at
6, 12, or 18 months
Iwarson et al., 20024 Observational data based on
vaccination 1994–96
HAVRIX 1440 25 health travelers aged 36–50
years, Sweden
SPR (anti-HAV AB 10 mIU/ml),
4–6 years: 72% (18)
GMC, 4–6 years: 32
Iwarson et al., 20045 Observational data based on
vaccination 1994–98
HAVRIX 1440 54 healthy travelers aged 31–50
years, Sweden
SPR (anti-HAV AB 10 mIU/ml),
4–8 years: 64.8% (35)
GMC, 4–8 years: 21
Extension of Iwarson et al., 2002
study
Five individuals followed-up for 8
years; one of them had detectable
antibodies after 8 years (GMT 69)
Landry et al., 200117 Observational study HAVRIX 1440 249 travelers aged 18 years,
124 received delayed booster
(max. 66 months) and 125
received two doses (6–12-month
interval), Switzerland
SPR (anti-HAV AB 33 mIU/ml),
2 years: 68%
GMT, 2 years: 116 (95% CI
78–175)
No statistically signiﬁcant
difference between pre-booster
GMT of delayed booster group and
group with two doses (89% SPR
after 6–12 months)
Lolekha et al., 200318 Data based on open,
randomized, clinical trial
AVAXIM 80 U
Three groups varying by
schedule of booster (month 6
(group A), 12 (group B), 18
(group C))
215 healthy children enrolled/
202 followed up, aged 5–10
years, Thailand
SPR group C (n = 66) (anti-HAV AB
20 mIU/ml), 1.5 years: >98%
GMT group C, 1.5 years: 124 (95%
CI 102–151)
Strong booster response, similar
across groups
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Table 1 (Continued )
Author Study type Intervention Population Outcome single dose vaccination Other results and comments
Mayorga Pe´rez et al., 20036 Data based on placebo-
controlled trial
EPAXAL, 0.5 ml 274 children aged 1.5–6 years
(122 in vaccine group),
Nicaragua
GMC, 15 months: 236.8 mIU/ml
(95% CI 173.4–323.5)
Nalin 199522 Data based on randomized
controlled trial
VAQTA, 25 U Children aged 2–17 years; 1037
enrolled in 1991; 519 received
vaccine, USA
SPR (anti-HAV AB 10 mIU/ml),
1.5 years: 89% (69/78)
GMT, 1.5 years: 39
Follow-up data of Werzberger
et al., 1992 Antibody levels 6–18
months after booster persisted
independent of pre-booster
antibody level (<99%)
Orr et al., 200619 Data based on open-label,
randomized prospective
study/
immunogenicity trial
VAQTA (226 individuals)
AVAXIM, 160 U (225 individuals)
451 healthy adults, aged 18–21
years, 95.4% males, recruits and
short-term military service
personnel (temporarily in
endemic regions), Israel
SPR (anti-HAV AB 10 mIU/ml), 2
years: 93%
GMC 2 years:
AVAXIM (n = 69): 56.8 (95% CI
44.4–72.7)
VAQTA (n = 61): 36.9 (95% CI
27.9–48.7)
Mixed (n = 46): 50.3 (95% CI
37–567.5)
Total (n = 176): 47.4 (95% CI
40.5–55.4)
No signiﬁcant differences between
VAQTA and AVAXIM in terms of
SPR at month 24
Strong booster response, including
those who were seronegative
before booster dose
Overbosch et al., 200523 Data based on open,
randomized, controlled
study/immunogenicity trial
conducted 1998–2002
Group A: Viatim (comb. AVAXIM
and Typhim Vi)
Group B: HA/Vi vaccine
360 healthy adult volunteers
enrolled/356 completed initial
study, aged 16–65 years; group
A: 177, group B: 179,
Netherlands, France
SPR (anti-HAV AB 20 mIU/ml),
3 years: group A, n = 112: 99.1%;
group B, n = 104: 99%
GMT, 3 years, group A (n = 112)
425 (95% CI 345–524); group B
(n = 103) 258 (95% CI 202–329)
Signiﬁcant increase in antibody
levels after booster dose
Sabanin et al., 201010 (Russian)
and Akimkin et al., 200724 (abstract)
Data based on
immunogenicity trial
AVAXIM, 160 U
HAVRIX 1440
Hep-A-in-Vac (HepA vaccine +
IG), used sequentially
15 000 adults (Russian military
personnel) vaccinated with one
dose (1996 and 2008)
300 AVAXIM-vaccinated
individuals assessed in 5 years
after vaccination
SPR (anti-HAV AB 20 mIU/ml),
(AVAXIM) 5 years: 90%
Hepatitis A incidence/acute cases:
No case of hepatitis A among
2002–2006 AVAXIM recipients
Decrease in incidence up to 2000
among military personnel in
general (4.0/1000 in 2000)
Only single-dose AVAXIM results
reported
anti-HAV AB, anti hepatitis A virus antibodies; 95% CI, 95% conﬁdence interval.
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Table 2
Hepatitis A virus (HAV) incidence and fulminant hepatic failure (FHF) following single-dose administration of inactivated hepatitis A vaccines
Author Study type Intervention Population Outcome single dose vaccination Other results and comments
Cervio et al., 201113 Retrospective
review of fulminant
hepatic failure
cases, based on
effectiveness trial
AVAXIM 80 U;
one-dose HepA
universal
immunization
program,
implemented in
Argentina in 2005
Children aged 3
months to 18 years,
admitted to
selected health
centers (1993–
2008)
Cases of HAV-associated FHF:
Pre-immunization program
(1993–2005):
54% (165/304) of FHF cases caused by
HAV infection
Post-immunization program
(2005–2008, i.e., up to 3 years after
program started): 27.7% (18/65) of FHF
cases caused by HAV infection
Population is a mixture of single- and
two-dose vaccine recipients, since
private sector uses two doses and public
sector uses one dose; the private sector
accounts for 12%
Vacchino 20089 Surveillance data AVAXIM 80 U;
one-dose HepA
universal
immunization
program,
implemented in
Argentina in 2005
Children aged 12
months
Hepatitis A incidence:
Pre-immunization program
(1995–2004): incidence range 70.5–
173.8/100 000
Pre-immunization program and pre-
outbreak (1998–2002): mean incidence
85.5/100 000 (95% CI 66.7–104.3)
Post-immunization program (2007, i.e.,
up to 2 years after program started):
incidence decreased by 88% to 10.3/100
000 compared to mean incidence
1998–2004
Age-group- and vaccinating-region-
speciﬁc decreases were all signiﬁcant
Data source was public health
surveillance
Decreases could be partially associated
with natural immunity from an
outbreak in 2003–2004
Issue with 12% of children receiving two
doses in Argentina
95% CI, 95% conﬁdence interval.
J.J. Ott, S.T. Wiersma / International Journal of Infectious Diseases 17 (2013) e939–e944 e943The representativeness of the study populations in the studies
may also be questioned, since they were very speciﬁc in terms of
age or other criteria (e.g., soldiers19).
Additional research is needed on long-term cohorts vaccinated
with a single dose of hepatitis A vaccine, as well as evaluations of
populations where this policy is in place (e.g., Argentina). Such
studies will guide future decisions on the need for and timing of
booster doses. In addition, more studies are required to assess the
cost savings and coverage of single-dose hepatitis A vaccination
policies. Predictions under various scenarios suggest that, com-
pared to no vaccination, the one-dose schedule vaccination in
Argentina could save over US$ 15 million, while a two-dose
schedule at months 12 and 18 would save US$ 13.8 million.
However, the cost-effectiveness of hepatitis A vaccination is highly
dependent on country-speciﬁc endemicity levels and within-
country variations and the comparison used.20 Taking into
consideration the endemicity level of hepatitis A, it is important
to study if the response to a natural exposure among single-dose
vaccine-protected individuals is comparable to a booster response,
which would be of signiﬁcant relevance for one-dose use in highly
endemic settings.
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manuscript for publication.
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